Hepatocellular Carcinoma | China In-Depth | China | 2021
The hepatocellular carcinoma market in China is poised to experience substantial market growth over the 2021-2031 period. In China, even though systemic targeted drugs for hepatocellular carcinoma are limited, with only a few agents beyond surgery or chemotherapy available, the pipeline of emerging therapies is promising. The key drivers of market growth will be the anticipated launch and uptake of several targeted therapies for hepatocellular carcinoma in China—particularly from the immune checkpoint inhibitors class—and the incorporation of many of these therapies into China’s National Reimbursement Drug List (NRDL); inclusion in the NRDL will secure better patient access. Additionally, following the recent reforms in China’s regulatory and reimbursement landscape, manufacturers—both domestic and multinational—will be increasingly incentivized to enter the growing hepatocellular carcinoma market over the coming years.
Questions Answered
- How large is China’s drug-treatable hepatocellular carcinoma population, and how will drug-treatment rates change during the forecast period?
- Which are the most commercially relevant drugs in China’s hepatocellular carcinoma market, and why? What are the interviewed experts’ insights into the current treatment options?
- What are the market access considerations and sales estimates for key therapies in the hepatocellular carcinoma pipeline in China? What are interviewed experts’ opinions of these therapies?
- What are the key drivers of and constraints in China’s hepatocellular carcinoma therapy market, and how will the market evolve over the forecast period?
Content Highlights
Geographies: China.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with medical oncologists. Supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of hepatocellular carcinoma in urban versus rural China. Clinically and market-relevant drug-treatable populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key hepatocellular carcinoma regimens through 2031, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: > 15 drugs; Phase II: > 13 drugs; Phase I/II: 7; coverage of select Phase I products.
Product Description
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
